NCT04386980

Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is Delayed

A Phase 3, Randomized, Multi-center, Blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intra-articular Resiniferatoxin Versus Placebo to Manage Pain in Patients With Osteoarthritis of the Knee Whose Total Knee Replacement Surgery is Delayed

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Sorrento Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Efficacy and safety study of resiniferatoxin versus placebo to manage pain in patients with knee osteoarthritis whose TKR surgery is delayed

Detailed description

This study evaluates the efficacy and safety of intra-articular resiniferatoxin (RTX) versus placebo to manage pain in patients with osteoarthritis of the knee whose Total Knee Replacement surgery is delayed.

Conditions

• Osteoarthritis, Knee
• Osteo Arthritis Knee
• Knee Pain Chronic

Interventions

Type	Name	Description
DRUG	Resiniferatoxin	Resiniferatoxin is a compound purified from natural sources.
DRUG	Placebo	Diluent in normal saline

Timeline

• Start date: 2021-04-01
• Primary completion: 2022-06-01
• Completion: 2022-06-01
• First posted: 2020-05-13
• Last updated: 2021-11-09

Regulatory

• FDA-regulated drug study